Johnson & Johnson
JNJ (NYSE)
Johnson & Johnson remains a highly regarded choice for investors seeking recession-resistant products and reliable dividends. With a solid dividend yield of 2.32% and impressive returns of 46.78% over the past year, this healthcare giant is well-positioned for continued growth. Analysts maintain a positive outlook, with a median 12-month price target of $220, reflecting confidence in its steady earnings potential.
Pros:
- Recession-resistant products
- Strong dividend history
Cons:
- Recent spin-off of Consumer Health
- Market competition
Johnson & Johnson (JNJ) presents a suitable investment opportunity for those seeking stability and consistent income through dividends, particularly in a recession-resistant sector like healthcare. With its solid performance metrics and positive analyst outlook, it may appeal to both conservative investors looking for reliable returns and those interested in long-term growth potential.